Immune-related myositis (irMyositis), mostly affecting elderly male cancer patients soon after the initiation of ICI treatment [110], appears to be the most common neuromuscular toxicity of anti-PD-1/anti-PDL1 and anti-CTLA-4 immunotherapy [111,112]. The gene discussed is CTLA4; the disease is cancer.